Ann: Independent data review commences for Ph 2 trial psilocybin, page-42

Talk about flogging a dead horse.
These 'concerns' have been addressed multiple times by multiple folks here. Months ago.

'Commencing' trials is one thing. Bringing them to completion is another. Good thing the BOD is looking further down the road than next month.

CR in two months? Are you ok, mate?

At current cash burn, we have two years worth of cash. By that time, we will have completed pivotal trials on at least two assets out of the three currently prioritised, perhaps all three. I expect we'll need a CR before all three pivotal trials can be completed, but I also think it is logical to expect the strategy will be to wait for positive results from at least one of two assets' pivotal trials, before committing to the full expense of the pivotal trial for the third asset. Or an asset sale will make the CR unnecessary. Either way, two very promising assets mean two very good chances at sending the SP to a place from where a CR won't affect your equinamity the way the previous CR seems to have.